

Total Cost of Insulin Workgroup

July 8, 2022 10:00 am – 1:00 pm Meeting Link

WORKGROUP MEMBERS	WORKGROUP MEMBERS	STAFF
Donna Sullivan – Chief Pharmacy Officer, HCA	Jenny Arnold – Washington Pharmacy Association	Nonye Connor – <i>Project Manager, HCA</i>
Mary Fliss – Deputy, Clinical Strategy and Operations, HCA	Leah Lindahl – Healthcare Distribution Alliance	Leta Evaskus - NW Prescription Drug Consortium Operations Manager
Barbara Hewitt Jones – Office of the Insurance Commissioner	LuGina Mendez-Harper – <i>PCMA</i>	Ryan Pistoresi - Assistant Chief Pharmacy Officer, HCA
William Hayes – Dept of Corrections	Lori Evans – Public member	Hayley De Carolis – <i>Center for Evidence-based Policy</i>
Lumi Nodit – Office of Attorney General	Laura Keller – <i>Public member</i>	Brittany Lazur – Center for Evidence- based Policy
Dan Gossett – School Employees Benefit Board	Amber Markland – Public member	Mandi Mizuta – Center for Evidence- based Policy
Kat Kahachatourian – Pharmacy Quality Assurance Commission	Jennifer Perkins – <i>Public member</i>	Sus an Stuard – <i>Center for Evidence-based Policy</i>
Chris Bandoli–Assoc. of Washington Health Plans		Mike Bonetto – Center for Evidence-based Policy
Kevin Wren – Washington Insulin For All		Dan Vizzini – Center for Evidence-based Policy

Main Outcome:

- Review 2022 Legislation (SB 1728) and Scope of Work
- Overview of HCA cost analysis work on Senate Bill 5203 (2021)
 - o Directs HCA to establish partnerships to produce, distribute or purchase generic prescription drugs and insulin.
- Review and discuss Workgroup survey results
- Workgroup discussion and feedback

No	Agenda Items	Time	Lead	Summary Meeting Notes
1.	 Welcome and Opening Business Introductions and icebreaker Meeting overview Announcement a bout changes to Open Public Meeting Act 	30	Mary Fliss – Deputy, Clinical Strategy and Operations, HCA	
2.	Review 2022 Legislation (SB 1728) and Scope of Work		Brittany Lazur – Center for Evidence-based Policy	
3.	Overview of HCA Cost Analysis from SB 5203		Dan Vizzini – Center for Evidence- based Policy	
4.	Break			
5.	Overview and Discussion of Workgroup Survey Results		Mi ke Bonetto – Center for Evidence-based Policy	
6.	. Next Steps		Mary Fliss – Deputy, Clinical Strategy and Operations, HCA	



	Action Items/Decisions									
#	Action Item	Assigned To:	Date Assigned:	Date Due:	Status					